More than $109M to be invested in COVID-19 research
June 27, 2020
Global Korean Post
To continue its efforts to address the health challenges of the COVID-19 pandemic in Canada and around the globe, the Government of Canada, through the Canadian Institutes of Health Research, along with provincial partners, launched a second rapid research funding competition on April 23, 2020.
On June 25, Patty Hajdu, Canada’s Minister of Health, announced the results of that funding competition: an investment of more than $109M over one year in COVID-19 research.
This investment will support 139 research teams from across the country that will focus on accelerating the development, testing, and implementation of measures to mitigate the rapid spread of COVID-19 and its negative consequences on people, communities, and health systems.
For example, researchers will focus on domestic and international clinical trials and scale-up promising existing projects that will increase our understanding of the efficacy and effectiveness of vaccines, therapeutics, and clinical approaches to COVID-19.
The research teams will also evaluate public health management, including containment strategies such as physical distancing and travel restrictions, and study at-risk populations. Their findings will inform decision-making and planning at national and international levels.
This research initiative includes a significant international component. More than a quarter of the 139 research teams will be working in collaboration with researchers in other countries. Many of these collaborations involve researchers in lower and middle-income countries where the greatest need exists for support in the pandemic.
By helping curb the virus overseas, these Canadian researchers will contribute to global health while protecting safety at home.
Projects funded through this call build on the initial investment of $55.3M to support 100 research projects on COVID-19 announced in March. The new projects will scale-up existing projects and address the gaps and priorities relevant to the current COVID-19 context.